RESEARCH ARTICLE

Pro-inflammatory cytokines in aqueous humor from dogs with anterior uveitis and post-operative ocular hypertension following phacoemulsification, primary glaucoma, and normal healthy eyes

Hannah M. Terhaar1, Michala de Linde Henriksen1*, Lisa K. Uhl1,2, Corey Boeckling3, Carolina Mehaffy3,4, Ann Hess5, Michael R. Lappin6

1 Department of Clinical Sciences, Comparative Ophthalmology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United States of America, 2 Pathology, Department of Veterinary Pathology, College of Veterinary Medicine, Iowa State University, Ames, IA, United States of America, 3 Bioanalysis and Omics (ARC-BIO), Colorado State University, Fort Collins, CO, United States of America, 4 Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United States of America, 5 Department of Statistics, College of Natural Sciences, Colorado State University, Fort Collins, CO, United States of America, 6 Department of Clinical Sciences, Center for Companion Animal Studies, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United States of America

* michala.henriksen@colostate.edu

Abstract

Background

The aim of this study was to evaluate the levels of pro-inflammatory cytokines in aqueous humor (AH) from dogs with anterior uveitis and post-operative ocular hypertension (POH) following phacoemulsification, in AH from dogs with primary glaucoma, and in normal healthy eyes with no signs of anterior uveitis or other ocular diseases.

Methods

An exploratory study including 21 samples of AH collected from 15 dogs; post-phacoemulsification with anterior uveitis and POH (‘POH group’, n = 10 samples), primary glaucoma (‘glaucoma group’, n = 6 samples), and normal (‘normal group’, n = 5 samples). Target mass spectrometry via multiple reaction monitoring (MRM-MS) with the Canine Cytokine Spike-Mix™ as internal standard was used to measure the pro-inflammatory cytokine levels.

Results

The MRM-MS method measured 15 pro-inflammatory cytokines. Tumor-necrosis-factor-alpha (TNFα) and interleukin-18 (IL-18) levels in AH were different between all three groups (glaucoma>POH>normal) (p = .05, p = .02, respectively). Additionally, IL-6 was higher in the ‘POH group’ compared to the ‘glaucoma group’ (p = .04) and IL-4 was higher in the ‘POH group’.
group’ compared to the ‘normal group’ \((p = .04)\). Intraocular pressure (IOP) was positively associated with increased AH levels of IL-18 (Spearman correlation = .64, \(p = .03\)).

**Conclusions**

MRM-MS using the Canine Cytokine SpikeMix™ as an internal standard was established as a method to detect pro-inflammatory cytokine levels in canine AH. The study demonstrated increased levels of IL-4, IL-6, IL-18, and TNFα in AH from canines with POH following phacoemulsification. Primary glaucomatous eyes had the highest levels of IL-18 and TNFα which may indicate that inflammation plays a role in the pathogenesis of primary glaucoma in dogs.

**Introduction**

Anterior uveitis is a painful and potentially blinding disease in humans and animals due to its ability to cause complications such as secondary glaucoma [1,2]. Breakdown of the blood aqueous barrier (BAB) by either exogenous or endogenous factors will cause anterior uveitis [3]. Exogenous factors include corneal ulcerations, cataracts causing lens induced uveitis, or trauma to the uvea from intraocular procedures such as cataract surgery (phacoemulsification) [3,4]. Endogenous factors, also known as ocular manifestations of systemic disease, include systemic infections, systemic neoplasia, or immune mediated disorders [3,4].

The two most common causes of cataracts in dogs are hereditary and diabetes mellitus [5]. Phacoemulsification causes significant anterior uveitis in the initial weeks following phacoemulsification (post-phaco). Anterior uveitis post-phaco is especially significant for dogs and human pediatric patients [6,7]. Significant post-phaco anterior uveitis, along with other contributing factors, can cause an elevation in intraocular pressure (IOP) which is distinct from glaucoma and referred to as post-operative ocular hypertension (POH) [6,8,9]. The time frames for POH reported in the literature vary, but it is described as a transient elevation in IOP within the first 24 hours through 14 days after surgery [6,10]. Retention of viscoelastic material in the anterior chamber has been implicated to increase the incidence of POH [11]. POH can lead to irreversible blindness due to retinal and optic nerve damage from the elevated IOP and there is a risk of chronic glaucoma; therefore, control of POH is an important factor in post-phaco patients [8].

Post-phaco anterior uveitis treatment for canine patients aims to control arachidonic acid-mediated inflammation by treatment with topical and systemic glucocorticoids and/or non-steroidal anti-inflammatory drugs (NSAIDs) [12]. These approaches have potential side effects, including gastrointestinal ulcers, renal failure, uncontrolled diabetes, and increased risk of corneal infections [13,14]. Finding alternative anti-inflammatory and immunotherapy treatment options has gained increased attention in ophthalmology research [15–18]. This can be facilitated by determining which pro-inflammatory cytokines are involved in post-phaco anterior uveitis. In humans with anterior uveitis, specific pro-inflammatory cytokines have been detected in aqueous humor (AH) including Interleukin (IL)-6, IL-8, IL-10, IL-13, IL-17, interferon-gamma (IFNγ), and tumor necrosis factor-alpha (TNFα) [19–22]. In dogs, IL-1β levels evaluated by enzyme-linked immunosorbent assay (ELISA) were increased in AH of eyes with cataracts [23]. In horses, IL-10, IL-17, IL-23, and IFNγ have shown potential for being important pro-inflammatory cytokines in horses with equine recurrent uveitis [24].
Various methods for measurement of pro-inflammatory cytokines in AH samples include polymerase chain reaction (PCR) assay, immunoassays such as ELISA, multiplexed or bead-based immunoassays, and flow cytometric analysis, as well as target mass spectrometry [19,22,25,26]. Multiplex bead assays have gained popularity due to their ability to permit examination of multiple analytes from a single sample, which is more rapid than other methods such as PCR and standard ELISA, however quality control and interlaboratory variation present challenges [27,28]. Additionally, multiplex assays can be impacted by unpredictable potential biological interactions between multiple cytokines and other molecules in a sample [29]. Target mass spectrometry may provide a more reliable and specific method of cytokine detection by evaluating proteins (cytokines) after enzymatic digestion and detection of selected precursor and transition ions from specific peptides [30]. Target mass spectrometry with the multiple reaction method (MRM-MS) has high specificity, high sensitivity, and multiplexing ability and appears to be a suitable alternative to immunoassays to screen for multiple cytokines. Additionally, MRM-MS allows the utilization of a single, small sample volume to quantify multiple low abundance analytes. This is beneficial in the evaluation of AH, because only limited fluid volume can be obtained from humans or small animals such as dogs [31]. Additionally, Canine Cytokine SpikeMix™ (JPT Peptide Technologies, Berlin, Germany) is a mixture of canine specific stable isotope labeled peptides that provides relative quantification of cytokines by mass spectrometry. Targeted proteomics with labeled peptides (by JPT peptide technologies) has been used in many different areas of research including biomarkers or diagnosis of osteoarthritis, Alzheimer’s disease including tear analysis, cancer and infectious diseases in humans [32–36]. Analysis with MRM-MS and Canine Cytokine SpikeMix™ could be a useful tool to characterize AH pro-inflammatory cytokines and monitor response to therapy in canine anterior uveitis.

The purpose of this study was to evaluate the levels of pro-inflammatory cytokines in AH from dogs with anterior uveitis and POH post-phaco, dogs with primary glaucoma, and in normal healthy eyes with no signs of anterior uveitis or other ocular diseases. MRM-MS was used as the method to evaluate the level of pro-inflammatory cytokines in AH. To the authors’ knowledge, this is the first study to describe pro-inflammatory cytokine levels in AH from dogs with anterior uveitis and POH post-phaco and primary glaucoma dogs. Additionally, this is the first study to evaluate the Canine Cytokine SpikeMix™ used as internal control in MRM-MS for its ability to provide relative quantification of pro-inflammatory cytokines in canine AH. 

**Materials and methods**

**Ethics statement**

Owners of dogs admitted to Colorado State University Veterinary Teaching Hospital have signed a client consent form that gives permission to use information regarding their dog’s diseases in future studies. The aqueous humor samples that were collected from patients in this study were either collected as a part of their treatment for anterior uveitis and POH or following enucleation of the eye. Aqueous humor from healthy research Beagles were collected with permission from institutional animal care and use committee (IACUC, protocol #18-1234A).

**Study design and population**

This is an exploratory study. Three groups were included in this study: The post-phacoemulsification group includes dogs with anterior uveitis and POH following surgery (‘POH group’). Primary glaucoma dogs (‘glaucoma group’). This group includes dogs with elevated intraocular pressure (IOP) due to primary / hereditary glaucoma from either goniodysgenesis or
anterior segment dysgenesis. The normal control dogs (‘normal group’). This group includes healthy research Beagle dogs with no signs of anterior uveitis or other ocular diseases. The ‘POH group’ and ‘glaucoma group’ were clinical patients at Colorado State University Veterinary Teaching Hospital between 2018–2019.

**Ophthalmic examination**

All dogs in this study received a physical examination by an ophthalmology resident and a complete ophthalmic examination by a board-certified veterinary ophthalmologist (DACVO) and by an ophthalmology resident at every appointment/rechecks and prior to any procedures such as phacoemulsification, aqueous paracentesis, or enucleation. A complete ophthalmic examination included the following steps: neuro-ophthalmic examination included menace response, palpebral reflex, dazzle reflex, and indirect and direct pupillary light reflex. The adnexa and anterior segment were examined with slit-lamp biomicroscopy (SL-17; Kowa Company Ltd., Tokyo, Japan), and the posterior segment was examined using an indirect ophthalmoscopy headset (Keeler Vantage; Keeler Instruments, Inc., Broomall, PA, USA) and a 28 diopter condensing lens (Volk; Mentor, OH, USA). Dilated indirect ophthalmoscopy was performed on the ‘normal group’ but not on the ‘POH group’ or ‘glaucoma group’ due to contraindication for dilation with elevated IOP [37–40]. Dilation of the pupil was facilitated by instillation of one drop (0.05 ml) tropicamide 1% ophthalmic solution (Akorn, Lake Forest, IL, USA) to both eyes. Diagnostic tests including tear production measurement with Schirmer tear test (Eye Care Product Manufacturing, LLC, Tuscon, AZ, USA), IOP measurement with rebound tonometry (Tono-Vet; Icare® Finland Oy, Espoo, Finland), and fluorescein stain to evaluate for corneal ulceration (Jorgensen Lab, Loveland, CO) were performed on all eyes.

**The ‘POH group’**

The ‘POH group’ consisted of dogs that underwent phacoemulsification for diabetic or inherited cataracts and developed anterior uveitis and POH within the first seven days post-phaco (Table 1). Inclusion criteria consisted of IOP elevation of ≥ 25 mmHg within the first seven days following phacoemulsification and with clinical signs of anterior uveitis including aqueous flare subjectively graded by the Kimura flare scale 0 to 4+ [41] by a DACVO and an ophthalmology resident. AH was collected from these dogs as a part of their treatment for anterior uveitis and POH post-phaco (see protocol below).

**Perioperative phacoemulsification protocol.** All dogs in the ‘POH group’ were treated with variable combinations of the follow medications prior to surgery (Table 2A): ofloxacin 0.3% ophthalmic solution (Apexa, Boise, ID), diclofenac 0.1% ophthalmic solution (Sandoz, Princeton, NJ), ketorolac 0.5% ophthalmic solution (Sandoz, Princeton, NJ), prednisolone acetate 1% ophthalmic suspension (Sandoz, Princeton, NJ), I-drop® Vet Plus ophthalmic lubrication (I-MED Animal Health, Dollard-des-Ormeaux, QC, Canada), OptixCare ophthalmic lubrication (Aventix, Burlington, Ontario, Canada), dorzolamide 2% ophthalmic solution (Bausch & Lomb, Bridgewater, NJ), and dorzolamide 2%/timolol 0.5% ophthalmic solution (Cosopt, Sandoz, Princeton, NJ). Treatment with diclofenac versus ketorolac was based on pre-referral medications started by the primary veterinarian. If the patient was not on a topical NSAID at the time of referral, they were placed on diclofenac 0.1% ophthalmic solution. Treatment with dorzolamide 2% versus dorzolamide 2%/timolol 0.5% was based on clinician preference and cardiovascular health of the patient. Timolol is a beta-blocker and results in a decreased heart rate when applied topically in canines [42]. On the morning of surgery, pre-surgical treatment consisted of the following topical drugs given in alternation every five minutes for two to three doses per drug: tropicamide 1% ophthalmic solution, phenylephrine 2.5%
ophthalmic solution (Paragon BioTeck, Inc., Portland, OR), diclofenac 0.1% ophthalmic solution, prednisolone acetate 1% ophthalmic suspension, and ofloxacin 0.3% ophthalmic solution.

Between anesthetic induction and beginning surgery, cefazolin (Hospira Inc., Lake Forest, IL) was administered intravenously (22 mg/kg); this was repeated every 90 minutes during surgery. A routine one-handed phacoemulsification procedure was performed by a DACVO or by an ophthalmology resident under direct supervision of a DACVO. Following a 3-mm clear Table 1. Clinical information of all patients.

| Group | ID number | Patient information | Eye | Time of collection | Ophthalmic disease | IOP\(^1\) (mmHg) | IOP\(^2\) (mmHg) | Flare |
|-------|-----------|---------------------|-----|-------------------|-------------------|------------------|------------------|-------|
| POH   | 01        | 9 year old FS Labrador Retriever | OD  | 1 day post-phacoemulsification | Diabetic cataracts | 12               | 45               | 3+    |
|       |           |                     | OS  | 1 day post-phacoemulsification | Diabetic cataracts | 50               | 50               | 4+    |
|       |           |                     | OS  | 6 days post-phacoemulsification | Diabetic cataracts | 25               | 50               | 2+    |
| POH   | 02        | 10 year old FS English Springer Spaniel | OD  | 1 day post-phacoemulsification | Diabetic cataracts | 29               | 48               | 1+    |
|       |           |                     | OS  | 1 day post-phacoemulsification | Diabetic cataracts | 35               | 40               | 1+    |
| POH   | 03        | 10 year old MC Labrador Retriever | OS  | 1 day post-phacoemulsification | Diabetic cataracts | 48               | 48               | 3+    |
|       |           |                     | OD  | 5 days post-phacoemulsification | Diabetic cataracts | 31               | 31               | 3+    |
| POH   | 04        | 8.5 year old MC Welsh Terrier | OD  | 2 days post-phacoemulsification | Diabetic cataracts | 12               | 33               | 3+    |
|       |           |                     | OS  | 2 days post-phacoemulsification | Diabetic cataracts | 26               | 26               | 3+    |
| POH   | 05        | 11 year old FS Cocker Spaniel | OD  | 1 day post-phacoemulsification | Hereditary cataract (hypermetry) | 23               | 50               | 3+    |
| Glaucoma | 06     | 2 year old FS Newfoundland | OD  | Post-enucleation | Glaucoma, anterior segment dysgenesis* | 65               | 65               | 3+    |
| Glaucoma | 07     | 2.5 year old FS mixed breed | OS  | Post-enucleation | Glaucoma, goniodygenesis* | 6               | 72               | 2+    |
| Glaucoma | 08     | 12 year old MC mixed breed | OS  | Post-enucleation | Glaucoma, goniodygenesis* | 69               | 74               | 1+    |
| Glaucoma | 09     | 5 year old MC English Springer Spaniel | OD  | Post-enucleation | Glaucoma, goniodygenesis* | 23               | 85               | Trace |
| Glaucoma | 10     | 10.5 year old MC West Highland White Terrier | OD  | 8 days post-phacoemulsification | Glaucoma, goniodygenesis† | 60               | 60               | Trace |
|       |           |                     | OS  | 8 days post-phacoemulsification | Glaucoma, goniodygenesis† | 54               | 54               | Trace |
| Normal | 11        | 1.5 year old MI Beagle | OS  | Aqueous paracentesis | Normal | 19               | NR               | 0     |
| Normal | 12        | 3 year old MI Beagle | OD  | Aqueous paracentesis | Normal | 19               | NR               | 0     |
| Normal | 13        | 3.5 year old MI Beagle | OD  | Aqueous paracentesis | Normal | 18               | NR               | 0     |
| Normal | 14        | 2.5 year old FI Beagle | OS  | Aqueous paracentesis | Normal | 18               | NR               | 0     |
| Normal | 15        | 1.5 year old FI Beagle | OD  | Aqueous paracentesis | Normal | 20               | NR               | 0     |

Aqueous humor (AH) samples were collected from three groups: 'POH group' (n = 10): Dogs with anterior uveitis and post-operative ocular hypertension (POH) following phacoemulsification, 'Glaucoma group' (n = 6): Dogs with primary glaucoma, 'Normal group' (n = 5): Healthy research beagles with no sign of anterior uveitis or other ocular diseases. Patient information, eye (OD = right eye, OS = left eye), time of collection, ophthalmic disease, intraocular pressure (IOP)\(^1\) – the day of AH collection, IOP\(^2\) – highest IOP measured for this patient, and subjective assessment of aqueous flare are described.

*confirmed via histopathology
†confirmed with gonioscopy, NR = not recorded. FI = female intact; FS = female spayed; MI = male intact; MC = male castrated.

https://doi.org/10.1371/journal.pone.0273449.t001
A corneal incision performed 1 mm from the limbus, Trypan blue 0.3 mL (I-Med Animal Health, Dollard-des-Ormeaux, QC, Canada) was injected into the anterior chamber to visualize the anterior lens capsule and facilitate capsulorrhexis. Trypan blue was followed by viscoelastic (I-Visc 1.8%, i-Medical Ophthalmic International Heidelberg GmbH, Mannheim, Germany) injected into the anterior chamber to retain its form and protect corneal endothelial cells from trauma and heat caused by the phacoemulsification process. The capsulorrhexis was performed by using a 22-gauge needle to create a hole in the anterior lens capsule. Utrata capsulorrhexis forceps were used to perform an approximately 4-5 mm diameter continuous curvilinear capsulorrhexis, after which phacoemulsification of the lens was performed.

Table 2. Pre- and post-operative surgical information for the 'POH group' and 'glaucoma group'.

| Table 2 | Pre- and post-operative surgical information for the 'POH group' and 'glaucoma group'. |
|---------|-------------------------------------------------------------------------------------|
| A       | ID number | Eye | Oral Medications | Ketonolac or Diclofenac | Ofloxacin | Dorzolamide or Dorzolamide/Timolol | Prednisolone | Phacoemulsification time (seconds) | IOL placed |
|---------|-----------|-----|------------------|-------------------------|-----------|----------------------------------|-------------|---------------------------------|-------------|
| **POH group (pre-sx)** |           |     |                  |                         |           |                                  |             |                                 |             |
| 01      | OD        | none | +                | +                       | +         | +                                | 4:30.70     | + 14 mm                         |             |
|         | OS        |      |                  |                         |           |                                  | 6:20.20     | + 14 mm                         |             |
| 02      | OD        | none | +                | -                       | -         | +                                | NR          | + 13 mm                         |             |
|         | OS        |      |                  |                         |           |                                  | NR          | + 13 mm                         |             |
| 03      | OS        | none | +                | -                       | -         | -                                | NR          | + 14 mm                         |             |
|         | OS        |      |                  |                         |           |                                  | NR          | -                               |             |
| 04      | OD        |      |                  |                         |           |                                  | 2:48.30     | -                               |             |
|         | OS        |      |                  |                         |           |                                  | 4:17.00     | -                               |             |
| 05      | OD        | none | +                | -                       | +         | -                                | NR          | + 13 mm                         |             |
|         | OS        |      |                  |                         |           |                                  |             |                                 |             |
| **B**   | ID number | Eye | Oral Medications | Ketonolac or Diclofenac | Ofloxacin | Dorzolamide or Dorzolamide/Timolol | Latanoprost | Prednisolone | Eye lubricant |
| **POH group (post-sx)** |           |     |                  |                         |           |                                  |             |                                 |             |
| 01      | OD        |      |                  |                         |           |                                  |             |                                 |             |
| 02      | OD        |      |                  |                         |           |                                  |             |                                 |             |
| 03      | OS        |      |                  |                         |           |                                  |             |                                 |             |
| 04      | OD        |      |                  |                         |           |                                  |             |                                 |             |
| 05      | OD        |      |                  |                         |           |                                  |             |                                 |             |
| **C**   | ID number | Eye | Dorzolamide or Dorzolamide/Timolol | Latanoprost | Prednisolone | Other | Phacoemulsification time (seconds) | IOL placed |
| **Glaucoma group** |           |     |                  |                         |           |                                 |             |                                 |             |
| 06      | OD        |      |                  |                         |           |                                 |             |                                 |             |
| 07      | OS        |      |                  |                         |           |                                 |             |                                 |             |
| 08      | OS        |      |                  |                         |           |                                 |             |                                 |             |
| 09      | OD        |      |                  |                         |           |                                 |             |                                 |             |
| 10      | OD        |      |                  |                         |           |                                 |             |                                 |             |

A) Pre-surgical and surgical characteristics (pre-sx) from the ‘POH group’ including pre-operative medications, phacoemulsification times (UST) when available, and if an intraocular lens (IOL) was placed (+ = IOL placed; — = no IOL placed). B) Post-surgical (post-sx) medications administered to the ‘POH group’. C) Medications prior to enucleation or aqueous paracentesis for the ‘glaucoma group’. Phacoemulsification times and if an IOL was placed are reported for one patient (patient 10) that developed glaucoma > 7 days post-phacoemulsification with no evidence of anterior uveitis. (+ = this medication(s) was used on this patient,— = this medication(s) was not used on this patient, NA = not applicable, NR = values not recorded in medical record).

https://doi.org/10.1371/journal.pone.0273449.t002
AMO Whitestar Signature phacoemulsification instrument (Johnson and Johnson Surgical Vision, Inc.; Santa Ana, CA) was used for all phacoemulsification surgeries. Irrigation/aspiration was used to remove any remaining cortex followed by placement of intraocular lenses (IOLs) (Acrivet, Bausch & Lomb, Bridgewater, NJ) in eyes where no contraindications such as posterior lens capsule rupture or tear were identified. Irrigation and aspiration of the anterior chamber to remove viscoelastic device were then performed for at least one minute in all eyes. The corneal incision was closed with three to four simple interrupted sutures using 8-0 Vicryl suture (Ethi-con, Somerville, NJ). Phacoemulsification times as well as IOL placement is documented for cases when available in Table 2.

Sequential tonometry was performed one hour after the dog was extubated and every one to two hours thereafter until the dog was discharged approximately five to six hours after surgery. Monitoring IOPs following phacoemulsification is common practice in veterinary ophthalmology for monitoring and early intervention of POH [6,43,44]. Topical medications were continued on an oral antibiotic as well as an oral anti-inflammatory (NSAID or steroid) for three to four weeks postoperatively (Table 2). All dogs were discharged the day of surgery and returned for recheck examination one day postoperatively as well as five to seven days postoperatively.

**Aqueous paracentesis and tissue plasminogen activator injection.** Dogs with IOPs ≥ 25 mmHg within the first seven days of surgery had an aqueous paracentesis performed for clinical management. The aqueous paracentesis allowed 0.2 ml of AH to be removed from the anterior chamber, followed by injection of 25 micrograms tissue plasminogen activator (TPA, Activase®; Genentech, San Francisco, CA). The aqueous paracentesis and TPA injection were performed to decrease IOP and to clear the iridocorneal angle of potential inflammatory debris such as fibrin.

Dogs were sedated based on clinician assessment of the patient temperament for an aqueous paracentesis to be safely performed. Prior to aqueous paracentesis, eyes were flushed three times with betadine solution (diluted 1:50) followed by application of three rounds (0.1 ml per round) of topical analgesia with proparacaine 0.5% ophthalmic solution (Sandoz, Princeton, NJ) applied to the eye. All eyes had a 27-gauge needle connected to a 1.0-milliliter syringe placed into the anterior chamber at the dorsal limbus by a veterinary ophthalmology resident supervised by a DACVO. Care was taken to avoid the corneal endothelium, iris, and lens. Following insertion into the anterior chamber, 0.2ml of AH was collected. The 1.0-milliliter syringe was removed and a new 1.0-milliliter syringe containing 25 micrograms TPA was connected to the 27-gauge needle for injection into the anterior chamber. The needle with syringe was removed from the anterior chamber and the insertion site at the limbus was compressed with a 0.3mm Bishop Harmon forceps for 30 seconds to prevent leakage of AH. The AH samples were stored in a -80°C freezer within 10 minutes of the aqueous paracentesis until analysis. Following aqueous paracentesis and TPA injection, the IOP was measured to verify the IOP was below 25 mmHg.

**The ‘glaucoma group’**

The ‘glaucoma group’ consisted of dogs with an elevated IOP and minimal to no evidence of clinical anterior uveitis. Inclusion criteria consisted of an elevated IOP > 25 mmHg, evidence of blindness on neuro-ophtalmic examination (negative menace, dazzle, and PLR) and diagnosed with primary / hereditary glaucoma confirmed as goniodysgenesis or anterior segment dysgenesis by histopathologic analysis of an enucleated eye or gonioscopy performed by a DACVO (Table 1). Table 2C documents the anti-glaucoma drugs and other topical
medications dogs had received prior to AH collection. When eyes from the ‘glaucoma group’ were enucleated, a routine subconjunctival enucleation was performed [45], and AH (0.2 mL) was collected with an aqueous paracentesis immediately following removal of the globe from the surgical field with a 27g needle and 1.0-milliliter syringe. The AH samples were stored in a -80°C freezer within 10 minutes after the aqueous paracentesis until analysis. The enucleated globes were placed in 10% neutral buffered formalin (Cole-Parmer, Vernon Hills, IL) and submitted to the Comparative Ocular Pathology Laboratory of Wisconsin (COPLOW; Madison, WI) for histopathology evaluation by board-certified veterinary pathologists.

The ‘normal group’

Dogs in the ‘normal group’ consisted of healthy research Beagles with normal IOP values and no signs of anterior uveitis or other ocular diseases on complete ophthalmic examination performed by a DACVO (MdLH) and an ophthalmology resident (Table 1).

Aqueous paracentesis. Normal healthy dogs with a normal ophthalmic examination were sedated with 0.3–0.4 mg/kg of IV butorphanol tartrate; 15 minutes following injection, the aqueous paracentesis procedure was performed. The aqueous paracentesis was performed as described above but with no TPA injection. Instead, the 27-gauge needle with syringe was removed from the anterior chamber and the penetrated area at the limbus was compressed with a 0.3 mm Bishop Harmon forceps for 30 seconds to prevent leaking of AH. The 0.2 ml AH was immediately stored in separate Eppendorf tubes in a -80°C freezer until analysis. All eyes were administered one drop (0.05ml) of topical ofloxacin 0.3% ophthalmic solution, one drop (0.05ml) of prednisolone acetate 1% ophthalmic suspension, one drop (0.05 ml) of atropine 1% ophthalmic solution (Apexa, Boise, ID), and one drop (0.05 ml) of I-drop Vet eye lubrication administered immediately following the procedure, but with five minutes between each eye medication.

Post-aqueous paracentesis treatment for ‘normal group’. Aqueous paracentesis induces anterior uveitis via BAB breakdown [46,47], therefore the ‘normal group’ of dogs were treated with topical ophthalmic medications according to the following procedure: ofloxacin 0.3% ophthalmic solution one drop (0.05ml) two times daily for five days and prednisolone acetate 1% ophthalmic suspension one drop (0.05 ml) two times daily for five days. Fluorescein stain was performed, and IOP measurement by tonometry was performed every day for five days post-procedure. Five days following the procedure, all dogs had a complete ophthalmic examination (as described under ‘ophthalmic examination’) performed to ensure all dogs had a normal ophthalmic examination with no signs of anterior uveitis before all topical medications were discontinued.

AH analysis with MRM-MS

The AH samples were submitted for analysis of pro-inflammatory cytokines to Colorado State University’s Bioanalysis and Omics (ARC-BIO) facility.

Development of an MRM-MS method to detect inflammatory cytokines in canine AH: Sample processing, preparation, and analysis. AH samples were concentrated using a 3KDa Molecular-Weight-Cut-Off Spin column (Amicon). Concentrated proteins (retentate) were subjected to three washes (buffer exchanges) with 10mM ammonium bicarbonate and then quantified in the nanodrop. When possible, 50ug of each sample was subjected to trypsin digestion followed by clean up using a C18 column as previously described [48]. Briefly, samples were reduced and alkylated with 5mM dithiothreitol and 5mM iodoacetamide. Trypsin (Pierce MS-Grade, Thermo Scientific) was added at an enzyme to substrate ratio of 1:25 and incubated at 37°C for 3-hours. Trypsin was deactivated with the addition of 5% trifluoroacetic
acid and desalted using Pierce C18 spin columns (Thermo Scientific) using the manufacturer’s instructions. Peptide eluate was dried in a vacuum evaporator. Digested samples were resuspended to an estimated final concentration of 2 μg/μl of the original protein concentration using 1:10 SpikeMix™-labeled peptides. Final peptide concentrations for each digested sample were estimated via nanodrop and final concentration was adjusted to 0.3μg/μl for all samples. A pool from all samples (1μl each) was made and used for optimization of the MRM-MS method.

An MRM-MS method to detect 15 pro-inflammatory cytokines; IL-1α, IL-1β, IL-3, IL-4, IL-5, IL-6, IL-8, IL-12α, IL-12β, IL-13, IL-18, TNFα, IFNγ, granulocyte-macrophage colony stimulating factor 2 (GMCSF2), and thrombopoietin (TPO) was developed using the Canine Cytokine SpikeMix™ (JPT Peptide Technologies: SpikeMix™ Cytokines Canine–Heavy (Cat # SPT-CYT-POOL-L-can). This mix contains heavy labeled peptides corresponding to 145 peptides from 68 canine inflammatory proteins. Peptide Mix was resuspended in 1 ml of TQS loading buffer (3% ACN, 0.1% FA in water). Peptide sequences for the 15 targets was imported into the Skyline software [49]. MassLynx was used to operate the Xevo TQ-S mass spectrometer (Waters corp) coupled to a M-class UPLC (Waters corp) and Trizaic source. Peptides were separated in an ion key column (iKey, 150 μm x 50mm Peptide BEH C18, 13Å, 1.7 μm). The mix was used to identify the best performing transition ions and ideal chromatographic conditions. Once a preliminary method was established, a series of iterations (2 μl injections of the 1:10 SpikeMix™ dilution spiked into a pool of canine AH (made of 1ul of each sample)) were carried out to optimize the method by identifying the best collision energy for all targets. The final method was used to test each of the individual samples separately [49].

The final optimized MRM-MS method included two methods which contained 15 targeted proteins and 28 representative peptides. One contained 15 target peptides and the other contained 13. Each method was optimized so at least 12 points per peak were captured for each transition ion. In addition, a second round of methods, each containing three transitions per peptide (instead of the usual five) and only one peptide per protein target, was also used for analysis to increase the sensitivity of the methods with at least 20 points per peak captured. The final optimized LC gradient was as follows: 10 minutes linear gradient from 5% Buffer B (0.1% formic acid in Acetonitrile), 95% Buffer A (0.1% formic acid in water) to 45% buffer B, 55% Buffer A, followed by a wash at 95% Buffer B, 5% Buffer A for five minutes and final equilibration at 5% Buffer B, 95% Buffer A for five minutes. The total time for each method was 20 minutes.

Results were presented as normalized Total Peak Area (nTPA) as exported by Skyline. In brief, TPA (corresponding to all monitored transitions per peptide) was normalized against the TPA of the corresponding heavy monitored transitions (from the canine cytokine SpikeMix™).

Statistical analysis
IOP values (mean ± SD) were compared between all three groups using a one-way analysis of variance (ANOVA). To assess pairwise comparisons between IOP values for ’POH’ and ’glaucoma groups’, unpaired Student’s t-test was used.

Summary statistics (min, median, max) were calculated for pro-inflammatory cytokine levels in each group. Summary plots indicate that many of the cytokines were not normally distributed (including zero values and some outliers), hence non-parametric approaches were used. Kruskal-Wallis test was used to compare pro-inflammatory cytokine levels and IOP values between the three groups (’POH group’, ‘glaucoma group’, ’normal group’). Dwass, Steel, Critchlow-Fligner (DSCF) method was used for further pairwise comparisons between groups...
(‘glaucoma group’ versus ‘normal group’, ‘POH group’ versus ‘glaucoma group’, and ‘normal group’ versus ‘POH group’). To assess correlation between IOP and each cytokine, Spearman correlations were calculated. Raw p-values were calculated, and Bonferroni’s method was used to account for multiple testing (corresponding to multiple pro-inflammatory cytokines) when a raw p-value was < .05. Analysis was done in SAS 9.4 (SAS Institute Inc., Cary, NC).

Results

Samples collected

Twenty-one (21) samples of AH from 15 dogs were collected and submitted for processing and analysis with MRM-MS (Table 1). The ‘POH group’ had 10 AH samples collected from five dogs (nine eyes) with one eye collected at two different time points. Dogs ranged in age from 1.5–11 years: one dog had a unilateral hereditary cataract (due to enucleation of the other globe), the remaining four dogs had bilateral diabetic cataracts. The ‘glaucoma group’ had six AH samples collected from five dogs (six eyes) ranging in age from 2–12 years of age: four samples were post-enucleation and histopathology revealed goniodysgenesis in three of the enucleated eyes and one eye was diagnosed with anterior segment dysgenesis. Other histopathology findings were similar among all eyes including optic nerve head cupping, gliosis, retinal atrophy, and minimal inflammation. Two samples in the ‘glaucoma group’ were from a single dog (via aqueous paracentesis) that developed glaucoma and blindness eight days postphaco. This dog was diagnosed with goniodysgenesis pre-phacoemulsification on its gonioscopy examination. Minimal signs of bilateral anterior uveitis (trace flare) were found on this dog’s ophthalmic examination prior to aqueous paracentesis. Aqueous paracentesis and TPA injection were performed as a last resort to decrease IOPs but with no effect. Due to the absence of visible evidence of anterior uveitis, the diagnosis of goniodysgenesis, and elevated IOPs with no effect of TPA, this dog was placed in the ‘glaucoma group’. Euthanasia was elected by the owner due to bilateral glaucoma, but necropsy was declined so histopathology is not available. In the ‘normal group’, five AH samples were collected from five healthy research Beagles with no signs of anterior uveitis or other ocular pathology. One eye was randomly picked from each dog. The dogs age ranged from 1.5–3.5 years.

MRM-MS testing of AH samples

The IOP prior to AH collection was highest in the ‘glaucoma group’ (46.2 ± 25.6 mmHg), followed by the ‘POH group’ (29.1 ± 12.8 mmHg) and the ‘normal group’ (18.8 ± 0.8 mmHg) with p = .03 (Table 1). With pairwise comparison between the ‘glaucoma group’ and ‘POH group’ immediately prior to AH collection, the ‘glaucoma group’ had the highest IOP followed by ‘POH group’, without statistical significance (p = .09). However, when comparing the highest recorded IOP for each patient, ‘glaucoma group’ (68.3 ± 11.0 mmHg) was higher than the ‘POH group’ (42.1 ± 9.0 mmHg) (p < .01).

Table 3 summarizes the pro-inflammatory cytokine levels for each group. TNFα and IL-18 levels in AH were different among all three groups with the ‘glaucoma group’ having the highest levels followed by the ‘POH group’ and ‘normal group’ (TNFα p = .05 and IL-18 p = .02). When comparing AH levels of IL-6, the ‘POH group’ had higher levels compared to the ‘glaucoma group’ (p = .04), but there was no evidence of differences between the ‘glaucoma group’ and ‘normal group’ (p = .57) or the ‘normal group’ and ‘POH group’ (p = .67). For IL-4, the ‘POH group’ had higher levels compared to the ‘normal group’ (p = .04). There was no evidence of differences between the ‘glaucoma group’ and ‘normal group’ (p = .11) or the ‘glaucoma group’ and ‘POH group’ (p = .72). There was no evidence of differences between the groups in pro-inflammatory cytokine levels for IL-1α, IL-1β, IL-3, IL-5, IL-8, IL-12α, IL-12β,
IL-13, IFNγ, GMCSF2, and TPO (Fig 1). The AH levels of IL-18 were positively correlated with increasing IOP (Spearman correlation = .64, \( p = .03 \)) (Fig 2).

Discussion

The present study demonstrates that MRM-MS using Canine Cytokine SpikeMix™ as an internal and normalization standard can detect pro-inflammatory cytokines in canine AH. Also, IL-4, IL-6, IL-18, and TNFα may be important pro-inflammatory cytokines in dogs with anterior uveitis and post-operative ocular hypertension after phacoemulsification surgery (‘POH group’), and normal eyes (‘normal group’). Reported values are nTPA \( E^{-4} \). Kruskal-Wallis test was used to compare between groups. Bonferroni’s adjustment was performed on any higher raw \( p \)-values to account for multiple variables.

\* indicates significant raw \( p \)-value
\*\* indicates significant \( p \)-value with Bonferroni’s adjustment.

Pro-inflammatory cytokine levels reported as median (min, max) for dogs with primary glaucoma (‘glaucoma group’), anterior uveitis and post-operative ocular hypertension after phacoemulsification surgery (‘POH group’), and normal eyes (‘normal group’). Reported values are nTPA \( E^{-4} \).

Table 3. Pro-inflammatory cytokine levels for all groups.

| Cytokine | Glaucoma | POH | Normal | Raw \( P \)-value | Bonferroni \( P \)-value |
|----------|----------|-----|--------|------------------|------------------------|
| IL-1α    | 41 (13, 410) | 36 (17, 140) | 42 (0, 69) | 0.92             |
| IL-1β    | 1.0 (0.47, 23) | 8.2 (0.69, 48) | 0.35 (0.30, 61) | 0.12             |
| IL-3     | 140 (120, 200) | 150 (87, 210) | 160 (100, 180) | 0.95             |
| IL-4     | 11 (7.1, 23) | 14 (3.2, 27) | 2.2 (0.052, 10) | 0.031* | 0.49 |
| IL-5     | 2.1 (0, 35) | 71 (0, 0770) | 2.1 (0, 35) | 0.13             |
| IL-6     | 2.0 (0, 12) | 21 (0.091, 49) | 7.9 (0, 76) | 0.065            |
| IL-8     | 120 (0, 1300) | 81 (53, 700) | 35 (11, 74) | 0.037* | 0.60 |
| IL-12α   | 61 (39, 130) | 62 (14, 260) | 42 (20, 100) | 0.74             |
| IL-12β   | 9.4 (0.12, 76) | 12 (0.18, 130) | 2.3 (0, 20) | 0.21             |
| IL-13    | 1.9 (0.29, 4.7) | 2.6 (0, 7.2) | 1.2 (0, 82) | 0.53             |
| IL-18    | 5900 (3700, 15000) | 3700 (2500, 6600) | 1500 (860, 1600) | 0.001* | 0.02** |
| CSF2     | 30 (0, 150) | 1.2 (0, 87) | 4.1 (0.65, 7.1) | 0.19             |
| IFNγ     | 1400 (3.4, 11000) | 600 (140, 2500) | 140 (0, 1100) | 0.036* | 0.57 |
| TNFα     | 170 (50, 390) | 110 (41, 150) | 8.5 (2.8, 28) | 0.003* | 0.05** |
| TPO      | 0.065 (0, 40) | 0.25 (0, 4.3) | 0.31 (0, 0.97) | 0.68             |

IL-13, IFNγ, GMCSF2, and TPO (Fig 1). The AH levels of IL-18 were positively correlated with increasing IOP (Spearman correlation = .64, \( p = .03 \)) (Fig 2).

Pro-inflammatory cytokines in canine aqueous humor

PLOS ONE | https://doi.org/10.1371/journal.pone.0273449 August 23, 2022 11 / 21
Fig 1. Cytokine levels in canine aqueous humor. Cytokine levels (normalized Total Peak Area, nTPA) in the aqueous humor (AH) of canine included Interleukin (IL) 1α, IL-1β, IL-3, IL-4, IL-5, IL-6, IL-8, IL-12α, IL-12β, IL-13, IL-18, Tumor necrosis factor-alpha (TNF-α), Interferon-gamma (IFNγ), granulocyte-macrophage colony stimulating factor 2 (GMCSF2), and thrombopoietin (TPO). TNFα and IL-18 levels in AH were...
response to a rise in IOP rather than the anterior uveitis. TNFα, a major pro-inflammatory cytokine, was higher in canine AH of post-phaco eyes compared to the normal control eyes in the current study. In accordance with these findings, TNFα plays a major role in human uveitis and has been detected in human patients following phacoemulsification surgery [19,20,51,55,56]. Neutralization or suppression of TNFα has shown to be effective in preventing experimental autoimmune uveitis [57,58]. However, in canine patients, Pinard et al. (2011) did not find detectable levels of TNFα in AH of canines following aqueous paracentesis to induce experimental uveitis [59]. This difference may be due to differing laboratory methods, or could represent a clinical difference between canine patients with anterior uveitis and POH following phacoemulsification and experimentally induced uveitis [47].

IL-4 and IL-6 levels were higher in the ‘POH group’ compared to the ‘normal group’ and ‘glaucoma group’, respectively. IL-4 and IL-6 have also been detected in human patients undergoing phacoemulsification [22,50,51]. Additionally, when evaluating AH from human patients with glaucoma, IL-4 has been undetectable [25,60]. Other studies in human glaucoma patients have found that IL-6 levels did not differ from the normal controls [25,61]. These findings of IL-4 and IL-6 in the human literature support that post-phaco patients with POH and glaucoma patients have a unique inflammatory response, which is likely to be applicable to our canine patients.

Treatment of anterior uveitis is often non-specific, involving topical and systemic glucocorticoids and/or NSAIDs. The use of long-term topical and systemic anti-inflammatory therapies can lead to side effects including lipid keratopathy, increased risk of ocular and systemic infections, gastrointestinal disease, renal disease, and iatrogenic hyperadrenocorticism [13,14,62]. Targeting specific pro-inflammatory cytokines has proven to be clinically beneficial in several

**Fig 2. IL-18 and intraocular pressure.** IL-18 levels (normalized Total Peak Area, nTPA) in the aqueous humor of canines were positively correlated with intraocular pressure (Spearman correlation = .64, \( p = .03 \)).

https://doi.org/10.1371/journal.pone.0273449.g002
autoimmune disorders in human medicine [63]. TNFα is a major target for treating both ophthalmic and systemic inflammatory and autoimmune disease [64,65]. HUMIRA™, a human monoclonal antibody ‘adalimumab’ is a TNFα inhibitor, which has shown positive results in the treatment of uveitis in humans [66]. In rats, CBD (Cannabidiol) has demonstrated inhibition of TNFα in experimentally induced uveitis as well as retinal TNFα release, which could be efficacious in management of autoimmune uveitis, retinal inflammation, and neuroprotection [67]. Other immunotherapies to treat human uveitis are being investigated, and newer studies with Janus kinase (JAK) inhibitors have shown promising results [17]. JAK inhibitors block multiple pro-inflammatory cytokines implicated in human uveitis such as IL-6 and IFNγ, resulting in disruption of Th1 differentiation [64,68,69]. These new therapies may be useful in our canine patients and further studies investigating effectiveness are warranted. Additionally, the use of target mass spectrometry could be utilized to detect inflammatory cytokines in treated versus untreated eyes, serving as an outcome measure for these future investigations.

Interestingly, AH levels of IL-18 and TNFα were higher in glaucoma eyes than POH eyes following phacoemulsification surgery. Patients with primary glaucoma were chosen as an IOP-matched group to evaluate for pro-inflammatory cytokines related to IOP rise rather than anterior uveitis and POH. There was no significant difference in IOP between the ‘POH group’ and ‘glaucoma group’ at the time of AH collection. Many studies show minimal to no detection of TNFα in AH of human glaucomatous eyes, but it has been suggested that TNFα levels may be higher in the vitreous humor compared to the AH [70]. Sawada et al. (2009) suggests that TNFα may signal neuronal damage in glaucomatous eyes due to secretion of TNFα from stressed posterior segment cells such as astrocytes, microglial cells, and retinal Müller glial cells [71–74]. Glaucoma patients in our study had end-stage, blind eyes with severe retinal atrophy and optic nerve head cupping on histopathology, possibly resulting in higher TNFα levels than reported in humans. Although the IOP did not differ between the ‘glaucoma group’ and ‘POH group’ at the time of AH sampling, when evaluating the highest reported IOP values from each patient, the ‘glaucoma group’ had significantly higher IOP values than the ‘POH group’. Additionally, IL-18 levels were positively correlated with increasing IOP. This may account for the higher pro-inflammatory cytokine values in the ‘glaucoma group’ compared to the ‘POH group’, suggesting that IL-18 may be associated with increased IOP rather than anterior uveitis and POH. Further investigation is needed to determine the pathophysiology of increased TNFα and IL-18 in primary glaucoma eyes.

In a study evaluating the histopathology of canine eyes with goniodysgenesis, over 85% of patients with acute glaucoma were found to have inflammatory cells in the trabecular meshwork. Therefore, the authors suggest that acute inflammation may play a pivotal role in the pathogenesis of the disease [75]. A more recent study evaluating the efficacy of anti-inflammatory therapy in patients with goniodysgenesis found an increased eye survival time in patients treated with anti-glaucoma and anti-inflammatory therapies, versus anti-glaucoma therapy alone [76]. However, these results were not statistically significant. The presence of major pro-inflammatory cytokines in the AH of canines with chronic primary glaucoma, may indicate anti-inflammatory therapies could be a beneficial adjunctive therapy to anti-glaucoma medications. However, this information should be interpreted with caution, as the small sample size does not allow validation of these conclusions, only chronic glaucomatous eyes were evaluated, and topical steroids have been associated with increased IOP in dogs [77].

Treatment for primary glaucoma involves various medical or surgical therapies aimed at delaying elevations in IOP and preserving vision for as long as possible [78]. However, elevations in IOP are inevitable and will eventually result in blind and painful eyes [78]. Therapeutics for primary glaucoma are an active area of research in both human and veterinary medicine [78,79]. A recent study by Plummer et al. (2021) demonstrated that 37.7% of
clinicians will treat primary glaucoma patients prophylactically with a topical anti-inflammatory [80]. However, the role of inflammation in primary glaucoma is largely unknown. A better understanding of pro-inflammatory cytokines involved in primary glaucoma may lead to advancements in medical therapy.

Most patients in our study were on topical or systemic anti-inflammatories prior to collection of AH which is likely to alter the cytokine profile. However, this data remains clinically relevant as treatment with topical anti-inflammatories post-phacoemulsification is gold standard. Analysis of the cytokines that remain elevated despite anti-inflammatory treatment may help direct future therapies to better control anterior uveitis and POH following phacoemulsification. Additionally, post-phaco and glaucoma patients were prescribed medications based on the individual patient needs and were not standardized in this study. Other medications, such as topical anti-glaucoma medications or antibiotics, may change the AH cytokine profile in canine patients, altering the results of the data in the present study. Latanoprost was given in a large number of patients prior to AH collection. Half the patients in the ‘glaucoma group’ (3 out of 6 eyes) were receiving topical latanoprost twice daily and 8 out of 10 eyes in the ‘POH group’ were receiving latanoprost as first line treatment for POH (Table 2). Latanoprost, a prostaglandin analog, decreases IOP by increasing AH outflow via the uveoscleral pathway but also results in breakdown of the BAB [81,82]. This could have resulted in elevated levels of cytokines in AH of both our glaucoma and POH patients.

Steroid-induced ocular hypertension is well documented in human patients [83]. Additionally, there is no significant difference in post-phacoemulsification anterior uveitis in humans when treated with topical NSAIDs versus corticosteroids [84]. However, the use of topical corticosteroids following phacoemulsification is common in veterinary ophthalmology to limit surgical-induced anterior uveitis and prevent the development of secondary glaucoma [6,43,44,85–87]. In canine patients, oral hydrocortisone and intravitreal triamcinolone do not induce elevations in IOP [88,89]. One canine study has demonstrated ocular hypertension in glaucomatous beagles with the use of topical dexamethasone [77]. Although we cannot rule out corticosteroids as a risk factor for POH development, control of post-operative uveitis is essential for a successful outcome following phacoemulsification in canines [87].

Retention of viscoelastic material following cataract surgery is a risk factor for the development of POH and is difficult to differentiate from POH induced by anterior uveitis [11]. Although, a study by Klein et al (2011), demonstrated a significant reduction in the incidence of POH when irrigation and aspiration of viscoelastic material was performed for 1 min at the end of phacoemulsification surgery [6]. In our study, irrigation and aspiration was performed for 1 min in all eyes to reduce the incidence of POH caused by retained viscoelastic material. Additionally, only eyes with signs of anterior uveitis were included. However, ensuring 100% removal of viscoelastic is not possible, making this a limitation of the study.

One inherent limitation of this study was the small sample size, making our results preliminary. A larger number of AH samples may lead to more statistically significant differences between groups. Additionally, we were unable to evaluate any potential differences between hereditary and diabetic cataracts following phacoemulsification surgery. A future study with more cases could evaluate pro-inflammatory cytokines in relation to blood glucose levels and serum pro-inflammatory cytokines collected at the same time as AH samples. Although many studies show no difference in post-operative outcomes between diabetic and non-diabetic patients, their cytokine profiles may differ [85,86,90]. This study involved simultaneous analysis of multiple factors (cytokines) from each sample. The Bonferroni correction was applied in this study to determine the significance of changes in pro-inflammatory cytokine levels. This statistical adjustment is conservative, and it may mask potential changes in the data.
Another limitation of our study is that phacoemulsification surgery was performed by either a DACVO or an ophthalmology resident under direct supervision of a DACVO. It is possible that increased surgery time could result in higher post-operative inflammation and complications in eyes with an ophthalmology resident performing surgery. However, studies in dogs have demonstrated that higher phacoemulsification times do not correlate with an increased risk of complications, such as glaucoma and POH \cite{6,43}. Correlation between surgeon experience and the proinflammatory cytokines in canine aqueous humor was not evaluated and requires future research with a larger sample size. Additionally, even experienced surgeons can come into complications and longer surgery times making these results clinically relevant.

Lastly, one dog in our study with goniodysgenesis on gonioscopy and bilateral blindness did not receive necropsy exam and histopathology of the globes. Although, gonioscopy is a primary diagnostic method in the evaluation of human and veterinary patients with glaucoma, it does not allow evaluation of the deeper filtration angle structures \cite{91}. The lack of histopathology on this patient is unlikely to affect our results given there were no outlier pro-inflammatory cytokine values in the 'glaucoma group'.

In conclusion, MRM-MS using the Canine Cytokine SpikeMix™ was able to detect levels of pro-inflammatory cytokines in canine AH. Dogs with anterior uveitis and POH following phacoemulsification surgery express elevated levels of IL-4, IL-6, IL-18, and TNFα in AH, which is consistent with the human literature. Additionally, dogs with glaucoma had higher levels of IL-18 and TNFα in AH compared to dogs with anterior uveitis and POH following phacoemulsification. This may indicate inflammation plays a role in the pathogenesis of glaucoma. The findings in this study emphasize the differential inflammatory responses and pro-inflammatory cytokine footprints in patients with glaucoma and POH following phacoemulsification.

Supporting information

S1 Table. Pro-inflammatory cytokine levels. Pro-inflammatory cytokine levels (normalized Total Peak Area, nTPA) for the ‘glaucoma group,’ ‘POH group,’ and ‘normal group.’ This table displays the sample identification, dog number (corresponding to Table 1), study group, IOP at the time of aqueous humor collection, and nTPA for all cytokines.

(S1 Table)

S2 Table. Statistical analysis of pro-inflammatory cytokine levels. The “SumStats” table displays the summary statistics for each cytokine (normalized Total Peak Area, nTPA) and group including median, minimum, maximum, and n = the number of samples in each group. The “Q1Result” show the comparison between all groups for each cytokine including the raw p-value (KW_Raw_p) and Bonferroni adjusted p-value (KW_Bon_P). It also includes raw p-values for pairwise comparisons between groups (DSCF_Raw_p). The “Q2Results” shows the correlation between IOP and each cytokine including n = number of samples in correlation, Spearman correlation (SpearCorr), raw p-value (Spear_Raw_p), and Bonferroni adjusted p-value (Spear_Bon_p).

(S2 Table)

Author Contributions

Formal analysis: Ann Hess.

Investigation: Lisa K. Uhl, Corey Boeckling, Carolina Mehaffy, Michael R. Lappin.
Methodology: Hannah M. Terhaar, Michala de Linde Henriksen, Corey Boeckling, Carolina Mehaffy, Michael R. Lappin.

Project administration: Michala de Linde Henriksen.

Supervision: Michala de Linde Henriksen, Michael R. Lappin.

Writing – original draft: Hannah M. Terhaar, Michala de Linde Henriksen.

Writing – review & editing: Hannah M. Terhaar, Michala de Linde Henriksen, Lisa K. Uhl, Carolina Mehaffy, Ann Hess, Michael R. Lappin.

References
1. Suttorp-Schulten M.S. and Rothova A., The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol, 1996. 80(9): p. 844–8. https://doi.org/10.1136/bjo.80.9.844 PMID: 8962842
2. Plummer C.E., Regnier A., and Gelatt K.N., The Canine Glaucomas, in Veterinary Ophthalmology, Gelatt K.N., Gilger B.C., and Kern T.J., Editors. 2013, John Wiley & Sons, Inc.: Ames, Iowa. p. 1050–1145.
3. Massa K.L., et al., Causes of uveitis in dogs: 102 cases (1989–2000). Vet Ophthalmol, 2002. 5(2): p. 93–8. https://doi.org/10.1046/j.1463-5224.2002.00217.x PMID: 12071865
4. Hendrix D.V., Diseases and Surgery of the Canine Anterior Uvea, in Veterinary Ophthalmology, Gelatt K.N., Gilger B.C., and Kern T.J., Editors. 2013, John Wiley & Sons, Inc.: Ames, Iowa. p. 1146–1198.
5. Davidson M. and Nelms S., Diseases of the Lens and Cataract Formation, in Veterinary Ophthalmology, Gelatt K.N., Gilger B.C., and Kern T.J., Editors. 2013, John Wiley & Sons, Inc.: Ames, Iowa. p. 1199–1233.
6. Klein H.E., et al., Postoperative complications and visual outcomes of phacoemulsification in 103 dogs (179 eyes): 2006–2008. Vet Ophthalmol, 2011. 14(2): p. 114–20. https://doi.org/10.1111/j.1463-5224.2010.00853.x PMID: 21366827
7. Ganesh S.K. and Mistry S., Phacoemulsification with Intraocular Lens Implantation in Pediatric Uveitis: A Retrospective Study. Ocul Immunol Inflamm, 2018. 26(2): p. 305–312. https://doi.org/10.1080/09273948.2016.1206944 PMID: 27598822
8. Wilkie D.A. and Collitz C.M., Surgery of the Lens, in Veterinary Ophthalmology, Gelatt K.N., Gilger B.C., and Kern T.J., Editors. 2013, John Wiley & Sons, Inc.: Ames, Iowa. p. 1234–1286.
9. Smith P., et al., Ocular hypertension following cataract surgery in dogs: 139 cases (1992–1993). Journal of the American Veterinary Medical Association, 1996. 209(1): p. 105. PMID: 8926189
10. Miller P.E., et al., Mechanisms of acute intraocular pressure increases after phacoemulsification lens extraction in dogs. Am J Vet Res, 1997. 58(10): p. 1159–65. PMID: 9328671
11. Wilkie D.A. and Willis A.M., Viscoelastic materials in veterinary ophthalmology. Vet Ophthalmol, 1999. 2(3): p. 147–153. https://doi.org/10.1046/j.1463-5224.1999.00076.x PMID: 11397257
12. Townsend W.M., Canine and feline uveitis. Vet Clin North Am Small Anim Pract, 2008. 38(2): p. 323–46, vii. https://doi.org/10.1016/j.cvsm.2007.12.004 PMID: 18299010
13. Ledbetter E.C., et al., The effect of topical ocular corticosteroid administration in dogs with experimentally induced latent canine herpesvirus-1 infection. Exp Eye Res, 2010. 90(6): p. 711–7. https://doi.org/10.1016/j.exer.2010.03.001 PMID: 20232324
14. Monteiro-Steagall B.P., Steagall P.V., and Lascelles B.D., Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. J Vet Intern Med, 2013. 27(5): p. 1011–9. https://doi.org/10.1111/jvim.12127 PMID: 23782347
15. Hasegawa E., et al., The effectiveness of adalimumab treatment for non-infectious uveitis. Immunol Med, 2019. 42(2): p. 79–83. https://doi.org/10.1080/25785826.2019.1642080 PMID: 31315546
16. Gamalero L., et al., Evidence-Based Treatment for Uveitis. Isr Med Assoc J, 2019. 21(7): p. 475–479. PMID: 31507124
17. Bauermann P., Heiligenhaus A., and Heinz C., Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis. Ocul Immunol Inflamm, 2019. 27(8): p. 1232–1234. https://doi.org/10.1080/09273948.2019.1605453 PMID: 31268748
18. Toguri J.T., et al., Anti-inflammatory effects of cannabinoid CB(2) receptor activation in endotoxin-induced uveitis. Br J Pharmacol, 2014. 171(6): p. 1448–61. https://doi.org/10.1111/bph.12545 PMID: 24308661
19. Weinstein J.E. and Pepple K.L., Cytokines in uveitis. Curr Opin Ophthalmol, 2018. 29(3): p. 267–274. https://doi.org/10.1097/ICU.0000000000000466 PMID: 29521875

20. Bauer D., et al., Multiplex Cytokine Analysis of Aqueous Humor in Juvenile Idiopathic Arthritis-Associated Anterior Uveitis With or Without Secondary Glaucoma. Front Immunol, 2018. 9: p. 708. https://doi.org/10.3389/fimmu.2018.00708 PMID: 29675026

21. van Laar J.A. and van Hagen P.M., Cytokines in uveitis. Clin Med Res, 2006. 4(4): p. 248–9. https://doi.org/10.3121/cmr.4.4.248 PMID: 16565392

22. Takase H., et al., Cytokine profile in aqueous humor and sera of patients with infectious or noninfectious uveitis. Invest Ophthalmol Vis Sci, 2006. 47(4): p. 1557–61. https://doi.org/10.1167/iovs.05-0836 PMID: 16565392

23. Ruiz T., Almeida A.B., and Ribeiro A.P., Concentrations of matrix metalloproteinase-2 and interleukin-1β in the aqueous humor of dogs with normal and cataractous eyes. Pesquisa Veterinária Brasileira, 2020. 40(3): p. 181–187.

24. Curto E., et al., Cytokine and chemokine profiles of aqueous humor and serum in horses with uveitis measured using multiplex bead immunoassay analysis. Vet Immunol Immunopathol, 2016. 182: p. 43–51. https://doi.org/10.1016/j.vetimm.2016.09.008 PMID: 27863549

25. Kokubun T., et al., Characteristic Profiles of Inflammatory Cytokines in the Aqueous Humor of Glaucomatous Eyes. Ocul Immunol Inflamm, 2018. 26(8): p. 1177–1188. https://doi.org/10.1080/09273948.2017.1327605 PMID: 28622063

26. Chistyakov D.V., et al., Comparative lipidomic analysis of inflammatory mediators in the aqueous humor and tear fluid of humans and rabbits. Metabolomics, 2020. 16(2): p. 27. https://doi.org/10.1007/s11306-020-1650-y PMID: 32052201

27. Stenken J.A. and Poschenrieder A.J., Bioanalytical chemistry of cytokines—a review. Anal Chim Acta, 2015. 853: p. 95–115. https://doi.org/10.1016/j.aca.2014.10.009 PMID: 25467452

28. Leng S.X., et al., ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci, 2008. 63(8): p. 879–84. https://doi.org/10.1093/gerona/63.8.879 PMID: 18772478

29. Liebler D.C. and Zimmerman L.J., Targeted quantitation of proteins by mass spectrometry. Biochemistry, 2013. 52(22): p. 3797–806. https://doi.org/10.1021/bi400110b PMID: 23517332

30. Parker C.E. and Borchers C.H., Mass spectrometry based biomarker discovery, verification, and validation—quality assurance and control of protein biomarker assays. Mol Oncol, 2014. 8(4): p. 840–58. https://doi.org/10.1016/j.molonc.2014.03.006 PMID: 24713096

31. Gilger B.C., Reeves K.A., and Salmon J.H., Ocular parameters related to drug delivery in the canine and equine eye: aqueous and vitreous humor volume and scleral surface area and thickness. Vet Ophthalmol, 2005. 8(4): p. 265–9. https://doi.org/10.1111/j.1463-5224.2005.00401.x PMID: 16008707

32. Spellman D.S., et al., Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer’s Disease Neuroimaging Initiative (ADNI) CSF. Proteomics Clin Appl, 2015. 9(7–8): p. 715–31. https://doi.org/10.1002/prca.201400178 PMID: 25676562

33. Kallo G., et al., Changes in the Chemical Barrier Composition of Tears in Alzheimer’s Disease Reveal Potential Tear Diagnostic Biomarkers. PLoS One, 2016. 11(6): p. e0158000. https://doi.org/10.1371/journal.pone.0158000 PMID: 27327445

34. Fernández-Puente P., et al., Multiplexed mass spectrometry monitoring of biomarker candidates for osteoarthritis. J Proteomics, 2017. 152: p. 216–225. https://doi.org/10.1016/j.jprot.2016.11.012 PMID: 27865793

35. Robak A., et al., Diagnosing pleural effusions using mass spectrometry-based multiplexed targeted proteomics quantitating mid- to high-abundance markers of cancer, infection/inflammation and tuberculosis. Sci Rep, 2022. 12(1): p. 3054. https://doi.org/10.1038/s41598-022-06924-y PMID: 35197508

36. Tomiyama E., et al., Proteomic analysis of urinary and tissue-exudative extracellular vesicles to discover novel bladder cancer biomarkers. Cancer Sci, 2021. 112(5): p. 2033–2045. https://doi.org/10.1111/cas.14881 PMID: 33721374

37. Lachkar Y. and Bouassida W., Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol, 2007. 18(2): p. 129–33. https://doi.org/10.1097/ICO.0b013e32808738d5 PMID: 17301614

38. Dulaurent T., et al., Effect of mydriasis induced by topical instillations of 0.5% tropicamide on the anterior segment in normotensive dogs using ultrasound biomicroscopy. Vet Ophthalmol, 2012. 15 Suppl 1: p. 8–13. https://doi.org/10.1111/j.1463-5224.2011.00898.x PMID: 22050918

39. Gomes F.E., et al., Effects of unilateral topical administration of 0.5% tropicamide on anterior segment morphology and intraocular pressure in normal cats and cats with primary congenital glaucoma. Vet
40. Kovalcuk L., et al., Comparison of the effects of topical and systemic atropine sulfate on intraocular pressure and pupil diameter in the normal canine eye. Vet Ophthalmol, 2015. 18(1): p. 43–9. https://doi.org/10.1111/vop.12138 PMID: 24428364

41. KIMURA S.J., THYGESON P., and HOGAN M.J., Signs and symptoms of uveitis. II. Classification of the posterior manifestations of uveitis. Am J Ophthalmol, 1959. 47(5 Pt 2): p. 171–6. https://doi.org/10.1016/s0002-9394(14)78240-6 PMID: 13649856

42. Plummer C.E., MacKay E.O., and Gelatt K.N., Comparison of the effects of topical administration of a fixed combination of dorzolamide-timolol to monotherapy with timolol or dorzolamide on IOP, pupil size, and heart rate in glaucomatous dogs. Vet Ophthalmol, 2006. 9(4): p. 245–9. https://doi.org/10.1111/j.1463-5224.2006.00469.x PMID: 16771760

43. Dees D.D., et al., Effect of prophylactic topical hypotensive medications in reducing the incidence of postoperative ocular hypertension after phacoemulsification in dogs. Vet Ophthalmol, 2017. 20(6): p. 514–521. https://doi.org/10.1111/vop.12461 PMID: 28164422

44. Newbold G.M., et al., Phacoemulsification outcomes in Boston terriers as compared to non-Boston terriers: a retrospective study (2002–2015). Vet Ophthalmol, 2018. 21(4): p. 353–361. https://doi.org/10.1111/vop.12517 PMID: 29380923

45. Gelatt K.N. and Whitley R.D., Surgery of the orbit, in Veterinary Ophthalmic Surgery, Gelatt K.N. and Gelatt J.P., Editors. 2011, Elsevier Saunders. p. 51–88.

46. Sato K., et al., Comparison of early posttreatment effects of two steroidal anti-inflammatory ophthalmic drugs on the ocular inflammatory response induced by paracentesis in healthy canine eyes. Vet Ophthalmol, 2019. 22(5): p. 607–613. https://doi.org/10.1111/vop.12629 PMID: 30716193

47. Allbaugh R.A., et al., Fluorophotometric and tonometric evaluation of ocular effects following aqueouscentesis performed with needles of various sizes in dogs. Am J Vet Res, 2011. 72(4): p. 556–61. https://doi.org/10.2460/ajvr.72.4.556 PMID: 21453158

48. Saveliev S.V., et al., Mass spectrometry compatible surfactant for optimized in-gel protein digestion. Anal Chem, 2013. 85(2): p. 907–14. https://doi.org/10.1021/ac302423t PMID: 23256507

49. MacLean B., et al., Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics, 2010. 26(7): p. 966–8. https://doi.org/10.1093/bioinformatics/btq054 PMID: 20147306

50. Dong N., et al., Aqueous cytokines as predictors of macular edema in patients with diabetes following uncomplicated phacoemulsification cataract surgery. BioMed research international, 2015. 2015. https://doi.org/10.1155/2015/126984 PMID: 25811020

51. Liu Y.-C., et al., Changes in aqueous oxidative stress, prostaglandins, and cytokines: comparisons of low-energy femtosecond laser–assisted cataract surgery versus conventional phacoemulsification. Journal of Cataract & Refractive Surgery, 2019. 45(2): p. 196–203. https://doi.org/10.1016/j.jcrs.2018.09.022 PMID: 30528516

52. Dembic Z., The cytokines of the immune system: the role of cytokines in disease related to immune response. 2015, Academic Press.

53. Caspi R.R., Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol, 2002. 21(2–3): p. 197–208. https://doi.org/10.1080/08830180212063 PMID: 12424843

54. Sun B., et al., Autoimmunity to a pathogenic retinal antigen begins as a balanced cytokine response that polarizes towards type 1 in a disease-susceptible and towards type 2 in a disease-resistant genotype. Int Immunol, 1999. 11(8): p. 1307–12. https://doi.org/10.1093/intimm/11.8.1307 PMID: 10421788

55. Chen W., et al., Cytokine Expression Profile in Aqueous Humor and Sera of Patients with Acute Anterior Uveitis. Curr Mol Med, 2015. 15(6): p. 543–9. https://doi.org/10.2174/1566524015666150731100012 PMID: 26238370

56. El-Asrar A.M., et al., Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol, 2011. 139(2): p. 177–84. https://doi.org/10.1016/j.clim.2011.01.014 PMID: 21334264

57. Sartani G., et al., Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci, 1996. 37(11): p. 2211–8. PMID: 8843907

58. Dick A.D., et al., Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun, 1998. 11(3): p. 255–64. https://doi.org/10.1016/j.jauto.1998.0197 PMID: 9693974
59. Pinard C.L., et al., Measurements of canine aqueous humor inflammatory mediators and the effect of carprofen following anterior chamber paracentesis. Vet Ophthalmol, 2011. 14(5): p. 296–303. https://doi.org/10.1111/j.1463-5224.2011.00876.x PMID: 21929606

60. Chua J., et al., Expression profile of inflammatory cytokines in aqueous from glaucomatous eyes. Mol Vis, 2012. 18: p. 431–8. PMID: 22355254

61. Duvesh R., et al., Multiplex cytokine analysis of aqueous humor from the patients with chronic primary angle closure glaucoma. Current Eye Research, 2017. 42(12): p. 1608–1613. https://doi.org/10.1080/02713683.2017.1362003 PMID: 28937875

62. Aharon M.A., Prittie J.E., and Buriko K., A review of associated controversies surrounding glucocorticoid use in veterinary emergency and critical care. J Vet Emerg Crit Care (San Antonio), 2017. 27(3): p. 267–277. https://doi.org/10.1111/vet.12603 PMID: 28449321

63. Nepom G.T., Ehlers M., and Mandrup-Poulsen T., Anti-cytokine therapies in T1D: Concepts and strategies. Clin Immunol, 2013. 149(3): p. 279–85. https://doi.org/10.1016/j.clim.2013.02.003 PMID: 23510726

64. Horai R. and Caspi R.R., Cytokines in autoimmune uveitis. J Interferon Cytokine Res, 2011. 31(10): p. 733–44. https://doi.org/10.1089/jir.2011.0042 PMID: 21787221

65. Ulsiri F., et al., Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. Sci Rep, 2017. 7(1): p. 5346. https://doi.org/10.1038/s41598-017-05759-2 PMID: 28706194

66. Neri P., et al., Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology. Int Ophthalmol, 2011. 31(2): p. 165–73. https://doi.org/10.1007/s10792-011-9430-3 PMID: 21287227

67. Burstein S., Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem, 2015. 23(7): p. 1377–85. https://doi.org/10.1016/j.bmc.2015.01.059 PMID: 25703248

68. Kontzias A., et al., Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol, 2012. 12(4): p. 464–70. https://doi.org/10.1016/j.coph.2012.06.008 PMID: 22819198

69. Gonzales A.J., et al., Oclicatibin (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther, 2014. 37(4): p. 317–24. https://doi.org/10.1111/jvp.12101 PMID: 24495176

70. Sugita S., et al., The role of soluble TNF receptors for TNF-alpha in uveitis. Invest Ophthalmol Vis Sci, 2007. 48(7): p. 3246–52. https://doi.org/10.1167/iovs.06-1444 PMID: 17591895

71. Lieberman A.P., et al., Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci U S A, 1989. 86(16): p. 6348–52. https://doi.org/10.1073/pnas.86.16.6348 PMID: 2474832

72. Tezel G. and Wax M.B., Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci, 2000. 20(23): p. 8693–700. https://doi.org/10.1523/J NEUROSCI.20-23-08693.2000 PMID: 11102475

73. Sawada H., et al., Tumor necrosis factor-alpha concentrations in the aqueous humor of patients with glaucoma. Invest Ophthalmol Vis Sci, 2010. 51(2): p. 903–6. https://doi.org/10.1167/iovs.09-4247 PMID: 19737888

74. Cotinet A., et al., Differential tumor necrosis factor and nitric oxide production in retinal Müller glial cells from C3H/HeN and C3H/HeJ mice. Ocul Immunol Inflamm, 1997. 5(2): p. 111–6. https://doi.org/10.1080/09279949709085059 PMID: 9234375

75. Reilly C.M., Morris R., and Dubielzig R.R., Canine goniodysgenesis-related glaucoma: a morphologic review of 100 cases looking at inflammation and pigment dispersion. Vet Ophthalmol, 2005. 8(4): p. 253–8. https://doi.org/10.1002/vop.12069 PMID: 16008705

76. Dees D.D., et al., Efficacy of prophylactic antiglaucoma and anti-inflammatory medications in canine primary angle-closure glaucoma: a multicenter retrospective study (2004–2012). Vet Ophthalmol, 2014. 17(3): p. 195–200. https://doi.org/10.1111/vop.12069 PMID: 23826812

77. Gelatt K.N. and Mackay E.O., The ocular hypertensive effects of topical 0.1% dexamethasone in beagles with inherited glaucoma. J Ocul Pharmacol Ther, 1998. 14(1): p. 57–66. https://doi.org/10.1089/jop.1998.14.57 PMID: 9493783

78. Komáromy A.M., et al., The future of canine glaucoma therapy. Vet Ophthalmol, 2019. 22(5): p. 726–740. https://doi.org/10.1111/vop.12678 PMID: 31106969

79. Badawi A.H., et al., Primary congenital glaucoma: An updated review. Saudi J Ophthalmol, 2019. 33(4): p. 382–388. https://doi.org/10.1016/j.sjopt.2019.02.002 PMID: 31920449
80. Plummer C.E., et al., Prophylactic anti-glaucoma therapy in dogs with primary glaucoma: A practitioner survey of current medical protocols. Vet Ophthalmol, 2021. 24 Suppl 1: p. 96–108. https://doi.org/10.1111/vop.12820 PMID: 32920915

81. Toris C.B., Gabelt B.T., and Kaufman P.L., Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol, 2008. 53 Suppl 1: p. S107–20. https://doi.org/10.1016/j.survophthal.2008.08.010 PMID: 19038618

82. Johnstone McLean N.S., Ward D.A., and Hendrix D.V., The effect of a single dose of topical 0.005% latanoprost and 2% dorzolamide/0.5% timolol combination on the blood-aqueous barrier in dogs: a pilot study. Vet Ophthalmol, 2008. 11(3): p. 158–61. https://doi.org/10.1111/j.1463-5224.2008.00609.x PMID: 18435656

83. Kersey J.P. and Broadway D.C., Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond), 2006. 20(4): p. 407–16. https://doi.org/10.1038/sj.eye.6701895 PMID: 15877093

84. el-Harazi S.M., et al., A randomized double-masked trial comparing ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing post-phacoemulsification flare and cells. Ophthal Mic Surg Lasers, 1998. 29(7): p. 539–44. PMID: 9674003

85. Dowler K.K., et al., Characterization of postoperative "fibrin web" formation after canine cataract surgery. Vet Ophthalmol, 2021. 24(1): p. 37–47. https://doi.org/10.1111/vop.12830 PMID: 32981182

86. Sigle K.J. and Nasisse M.P., Long-term complications after phacoemulsification for cataract removal in dogs: 172 cases (1995–2002). J Am Vet Med Assoc, 2006. 228(1): p. 74–9. https://doi.org/10.2460/javma.228.1.74 PMID: 16426170

87. Michau T., Surgery of the Lens, in Veterinary Ophthalmology, Gelatt K.N., Editor. 2021, John Wiley & Sons, Inc.: Hoboken, NJ. p. 1371–1458.

88. Herring I.P., Herring E.S., and Ward D.L., Effect of orally administered hydrocortisone on intraocular pressure in nonglaucomatous dogs. Vet Ophthalmol, 2004. 7(6): p. 381–4. https://doi.org/10.1111/j.1463-5224.2004.04036.x PMID: 15511278

89. Molleda J.M., et al., The ocular effects of intravitreal triamcinolone acetonide in dogs. Vet J, 2008. 176(3): p. 326–32. https://doi.org/10.1016/j.tvjl.2007.02.031 PMID: 17466546

90. Bras I.D., et al., Posterior capsular opacification in diabetic and nondiabetic canine patients following cataract surgery. Vet Ophthalmol, 2006. 9(5): p. 317–27. https://doi.org/10.1111/j.1463-5224.2006.00458.x PMID: 16939460

91. Ekesten B. and Narfström K., Correlation of morphologic features of the iridocorneal angle to intraocular pressure in Samoyeds. Am J Vet Res, 1991. 52(11): p. 1875–8. PMID: 1785731